| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €117.60 |
| 52 Week High | €123.75 |
| 52 Week Low | €108.75 |
| Beta | 0.64 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0.51% |
| 3 Year Change | n/a |
| 5 Year Change | -13.28% |
| Change since IPO | 104.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPSE.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | 0.5% | 13.2% | 24.9% |
Return vs Industry: IPSE.F underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: IPSE.F underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| IPSE.F volatility | |
|---|---|
| IPSE.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPSE.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IPSE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| IPSE.F fundamental statistics | |
|---|---|
| Market cap | US$9.93b |
| Earnings (TTM) | US$660.42m |
| Revenue (TTM) | US$3.54b |
15.0x
P/E Ratio2.8x
P/S RatioIs IPSE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPSE.F income statement (TTM) | |
|---|---|
| Revenue | €3.31b |
| Cost of Revenue | €571.20m |
| Gross Profit | €2.74b |
| Other Expenses | €2.12b |
| Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 7.47 |
| Gross Margin | 82.72% |
| Net Profit Margin | 18.66% |
| Debt/Equity Ratio | 9.6% |
How did IPSE.F perform over the long term?
See historical performance and comparison